Advance

INADA Masahiro

    Department of Medicine　Lecturer in Medical School
Last Updated :2024/04/25

Researcher Information

Degree

  • Doctor of Medical Science（2018/03 Kindai University）

J-Global ID

Research Interests

  • Radiotherapy   Radiation Oncology   

Research Areas

  • Life sciences / Radiology

Academic & Professional Experience

  • 2020/04 - Today  Kindai University Faculty of MedicineDepartment of Radiation Oncology医学部講師
  • 2014/04 - 2020/03  Kindai University, Faculty of MedicineDepartment of Radiation Oncology助教
  • 2012/04 - 2014/03  Kinki University Hospital研修医

Education

  • 2014/04 - 2018/03  近畿大学 大学院 医学系医学科  放射線腫瘍学
  • 2006/04 - 2012/03  Kinki University  Faculty of Medicine

Association Memberships

  • JAPAN PSYCHO ONCOLOGY SOCIETY   JAPAN ESOPHAGEAL SOCIETY   JAPAN RADIOLOGICAL SOCIETY   JAPANESE SOCIETY FOR RADIATION ONCOLOGY   日本放射線腫瘍学研究機構   日本癌治療学会   JAPAN SOCIETY FOR HEAD AND NECK CANCER   

Published Papers

  • Takuya Uehara; Yasumasa Nishimura; Kazuki Ishikawa; Masahiro Inada; Kenji Matsumoto; Hiroshi Doi; Hajime Monzen; Yukinori Matsuo
    Journal of radiation research 2024/01 
    The present study aimed to evaluate whether an adapted plan with Ethos™ could be used for pharyngeal cancer. Ten patients with pharyngeal cancer who underwent chemoradiotherapy with available daily cone-beam computed tomography (CBCT) data were included. Simulated treatments were generated on the Ethos™ treatment emulator using CBCTs every four to five fractions for two plans: adapted and scheduled. The simulated treatments were divided into three groups: early (first-second week), middle (third-fourth week), and late (fifth-seventh week) periods. Dose-volume histogram parameters were compared for each period between the adapted and scheduled plans in terms of the planning target volume (PTV) (D98%, D95%, D50% and D2%), spinal cord (Dmax and D1cc), brainstem (Dmax) and ipsilateral and contralateral parotid glands (Dmedian and Dmean). The PTV D98%, D95% and D2% of the adapted plan were significantly higher than those of the scheduled plans in all periods, except for D98% in the late period. The adapted plan significantly reduced the spinal cord Dmax and D1cc compared with the scheduled plan in all periods. Ipsilateral and contralateral parotid glands Dmean of the adapted plan were lower than those of scheduled plan in the late period. In conclusion, the present study revealed that the adapted plans could maintain PTV coverage while reducing the doses to organs at risk in each period compared with scheduled plans.
  • Saori Tatsuno; Hiroshi Doi; Masahiro Inada; Takuya Uehara; Yutaro Wada; Kazuki Ishikawa; Kaoru Tanaka; Mutsukazu Kitano; Yasumasa Nishimura
    Strahlentherapie und Onkologie Springer Science and Business Media LLC 0179-7158 2023/11
  • Hiroshi Doi; Aritoshi Ri; Masahiro Inada; Saori Tatsuno; Takuya Uehara; Tomohiro Matsuura; Kazuki Ishikawa; Kiyoshi Nakamatsu; Makoto Hosono; Yasumasa Nishimura
    International journal of clinical oncology 2023/10 
    BACKGROUND: This study aimed to reveal the long-term outcomes and late toxicities (> 5 years) after definitive intensity-modulated radiation therapy (IMRT) in patients with nasopharyngeal carcinoma (NPC). METHODS: Data from 43 patients (median age, 55 years; range, 17-72 years) with NPC who underwent definitive IMRT between 2001 and 2018 were analyzed. All patients were alive and disease-free 5 years after IMRT. A total dose of 70 (range, 66-70) Gy was delivered in 35 (33-35) fractions with concurrent cisplatin chemotherapy. RESULTS: The median follow-up duration was 119 (range, 61.5-242.1) months. Three patients developed locoregional failure at 79, 92, and 149 months after IMRT, respectively. Of these, 2 patients died of disease progression at 136 and 153 months after IMRT. One patient died of aspiration pneumonia 141 months after IMRT, despite salvage of the recurrent tumor by re-irradiation. In addition, one patient died of aspiration pneumonia 62 months after the IMRT. Thus, the 10-year overall survival, progression-free survival, and locoregional control rates were 98%, 92%, and 94%, respectively. Grade ≥ 2 and ≥ 3 late toxicities were observed in 28 (65%) and 9 (21%) patients, respectively. Nine second primary cancers, including five tongue cancers and two external auditory canal carcinomas, were observed in seven (16%) patients. CONCLUSION: Late recurrences, severe late toxicities, and second primary cancers were observed > 5 years after IMRT. A long-term follow-up of > 5 years is needed in patients with NPC.
  • 【肝胆膵癌に対する放射線治療:2023 Update】膵癌 膵NENに対するペプチド受容体放射性核種療法(PRRT)
    細野 眞; 李 在俊; 立野 沙織; 福田 隼己; 石田 奈緒子; 植原 拓也; 稲田 正浩; 松浦 知弘; 土井 啓至; 中松 清志; 門前 一; 松尾 幸憲
    肝胆膵 (株)アークメディア 87 (1) 79 - 84 0389-4991 2023/07
  • Ito T; Monzen H; Kubo K; Kosaka H; Yanagi Y; Sakai Y; Inada M; Doi H; Nishimura Y
    Reports of Practical Oncology and Radiotherapy VM Media Group sp. z o.o 28 (3) 399 - 406 1507-1367 2023/06 [Refereed]
  • Wada Y; Monzen H; Ishida N; Ri A; Tatsuno S; Uehara T; Inada M; Doi H; Nakamatsu K; Hosono M; Nishimura Y
    Medical Dosimetry 48 (3) 193 - 196 2023/05 [Refereed]
  • Takafumi Minami; Kazutoshi Fujita; Mamoru Hashimoto; Mitsuhisa Nishimoto; Shogo Adomi; Eri Banno; Masahiro Nozawa; Kazuhiro Nose; Kazuhiro Yoshimura; Masahiro Inada; Masaki Yokokawa; Kiyoshi Nakamatsu; Hirotsugu Uemura
    World journal of urology 2023/04 
    PURPOSE: To investigate the risk of bladder cancer (BCa) in patients treated with brachytherapy for prostate cancer (PCa). METHODS: We retrospectively analyzed 583 patients with PCa who underwent brachytherapy with or without external beam radiotherapy (EBRT). We analyzed the disease-free survival (DFS) of BCa in patients with PCa who underwent brachytherapy with or without EBRT. We performed multivariate Cox regression analyses of DFS using age, EBRT, and Brinkman index (BI) score (number of cigarettes smoked per day × number of years smoking) ≥ 200 as variables for BCa after brachytherapy. RESULTS: Fourteen patients (2.4%) developed BCa after brachytherapy with or without EBRT. The percentage of high-grade urothelial carcinoma (UC) was 63.6%. A total of 85.7% of patients had non-muscle invasive BCa, and 14.3% of patients had muscle invasive BCa. DFS was longer in brachytherapy monotherapy than in combination therapy (brachytherapy + EBRT). Multivariate Cox regression analysis showed that a BI score ≥ 200 (Hazard Ratio (HR 8.61; 95% Confidence Interval (CI) 1.12-65.98) and EBRT combination (HR 3.29; 95% CI 1.03-10.52) were significantly associated with BCa development in patients with PCa treated with brachytherapy. Furthermore, patients with BI score ≥ 200 and EBRT combination had a significantly higher risk of BCa compared with patients with BI score < 200 (HR Log-rank test P = 0.010). CONCLUSION: Most cases of BCa after brachytherapy with or without EBRT are high grade and invasive. We hypothesized that the EBRT combination might be a risk factor for BCa in patients with PCa who underwent brachytherapy.
  • Inada M; Nishimura Y; Hanaoka K; Nakamatsu K; Doi H; Uehara T; Komanishi M; Ishii K; Kaida H; Hosono M
    Radiotherapy and Oncology In press 2023/01 [Refereed]
  • Inagaki T; Doi H; Inada M; Ishida N; Ri A; Tatsuno S; Wada Y; Uehara T; Nakamatsu K; Hosono M; Nishimura Y
    Strahlentherapie und Onkologie Online ahead of print. 2022/12 [Refereed]
  • 肝機能障害を有する食道癌患者に対する放射線治療の検討
    稲田 正浩; 石川 一樹; 西村 恭昌
    日本食道学会学術集会プログラム・抄録集 (NPO)日本食道学会 76回 158 - 158 2022/09
  • Oguma Y; Hosono M; Okajima K; Inoue E; Nakamatsu K; Doi H; Matsuura T; Inada M; Uehara T; Wada Y; Ri A; Yamamoto Y; Yoshimura Y; Uemura H; Nishimura Y
    Radiation 2 (3) 273 - 284 2022/09 [Refereed]
  • Masahiro Inada; Yasumasa Nishimura; Satoshi Ishikura; Kazuki Ishikawa; Naoya Murakami; Takeshi Kodaira; Yoshinori Ito; Kazuhiko Tsuchiya; Yuji Murakami; Junichi Saito; Tetsuo Akimoto; Kensei Nakata; Michio Yoshimura; Teruki Teshima; Takashi Toshiyasu; Yosuke Ota; Toshiyuki Minemura; Hidetoshi Shimizu; Masahiro Hiraoka
    Radiation oncology (London, England) 17 (1) 133 - 133 2022/07 [Refereed]
     
    BACKGROUND: JCOG1015A1 is an ancillary research study to determine the organ-specific dose constraints in head and neck carcinoma treated with intensity-modulated radiation therapy (IMRT) using data from JCOG1015. METHODS: Individual patient data and dose-volume histograms of organs at risk (OAR) were collected from 74 patients with nasopharyngeal carcinoma treated with IMRT who enrolled in JCOG1015. The incidence of late toxicities was evaluated using the cumulative incidence method or prevalence proportion. ROC analysis was used to estimate the optimal DVH cut-off value that predicted toxicities. RESULTS: The 5-year cumulative incidences of Grade (G) 1 myelitis, ≥ G1 central nervous system (CNS) necrosis, G2 optic nerve disorder, ≥ G2 dysphagia, ≥ G2 laryngeal edema, ≥ G2 hearing impaired, ≥ G2 middle ear inflammation, and ≥ G1 hypothyroidism were 10%, 5%, 2%, 11%, 5%, 26%, 34%, and 34%, respectively. Significant associations between DVH parameters and incidences of toxicities were observed in the brainstem for myelitis (D1cc ≥ 55.8 Gy), in the brain for CNS necrosis (D1cc ≥ 72.1 Gy), in the eyeball for optic nerve disorder (Dmax ≥ 36.6 Gy), and in the ipsilateral inner ear for hearing impaired (Dmean ≥ 44 Gy). The optic nerve, pharyngeal constrictor muscle (PCM), and thyroid showed tendencies between DVH parameters and toxicity incidence. The prevalence proportion of G2 xerostomia at 2 years was 17 versus 6% (contralateral parotid gland Dmean ≥ 25.8 Gy vs less). CONCLUSIONS: The dose constraint criteria were appropriate for most OAR in this study, although more strict dose constraints might be necessary for the inner ear, PCM, and brainstem.
  • Takaya Inagaki; Hiroshi Doi; Naoko Ishida; Aritoshi Ri; Saori Tatsuno; Yutaro Wada; Takuya Uehara; Masahiro Inada; Kiyoshi Nakamatsu; Makoto Hosono; Yasumasa Nishimura
    Cancers 14 (4) 2022/02 [Refereed]
     
    Stereotactic body radiotherapy (SBRT) is a treatment option for early-stage lung cancer. The purpose of this study was to investigate the optimal dose distribution and prognostic factors for local control (LC) after SBRT for lung cancer. A total of 104 lung tumors from 100 patients who underwent SBRT using various treatment regimens were analyzed. Dose distributions were corrected to the biologically effective dose (BED). Clinical and dosimetric factors were tested for association with LC after SBRT. The median follow-up time was 23.8 months (range, 3.4-109.8 months) after SBRT. The 1- and 3-year LC rates were 95.7% and 87.7%, respectively. In univariate and multivariate analyses, pathologically confirmed squamous cell carcinoma (SQ), T2 tumor stage, and a Dmax < 125 Gy (BED10) were associated with worse LC. The LC rate was significantly lower in SQ than in non-SQ among tumors that received a Dmax < 125 Gy (BED10) (p = 0.016). However, there were no significant differences in LC rate between SQ and non-SQ among tumors receiving a Dmax ≥ 125 Gy (BED10) (p = 0.198). To conclude, SQ, T2 stage, and a Dmax < 125 Gy (BED10) were associated with poorer LC. LC may be improved by a higher Dmax of the planning target volume.
  • Takuya Uehara; Hajime Monzen; Mikoto Tamura; Masahiro Inada; Masakazu Otsuka; Hiroshi Doi; Kenji Matsumoto; Yasumasa Nishimura
    Radiation Oncology Springer Science and Business Media LLC 16 (1) 2021/12 [Refereed]
     
    Abstract Background The use of total body irradiation (TBI) with linac-based volumetric modulated arc therapy (VMAT) has been steadily increasing. Helical tomotherapy has been applied in TBI and total marrow irradiation to reduce the dose to critical organs, especially the lungs. However, the methodology of TBI with Halcyon™ linac remains unclear. This study aimed to evaluate whether VMAT with Halcyon™ linac can be clinically used for TBI. Methods VMAT planning with Halcyon™ linac was conducted using a whole-body computed tomography data set. The planning target volume (PTV) included the body cropped 3 mm from the source. A dose of 12 Gy in six fractions was prescribed for 50% of the PTV. The organs at risk (OARs) included the lens, lungs, kidneys, and testes. Results The PTV D98%, D95%, D50%, and D2% were 8.9 (74.2%), 10.1 (84.2%), 12.6 (105%), and 14.2 Gy (118%), respectively. The homogeneity index was 0.42. For OARs, the Dmean of the lungs, kidneys, lens, and testes were 9.6, 8.5, 8.9, and 4.4 Gy, respectively. The V12Gy of the lungs and kidneys were 4.5% and 0%, respectively. The Dmax of the testes was 5.8 Gy. Contouring took 1–2 h. Dose calculation and optimization was performed for 3–4 h. Quality assurance (QA) took 2–3 h. The treatment duration was 23 min. Conclusions A planning study of TBI with Halcyon™ to set up VMAT-TBI, dosimetric evaluation, and pretreatment QA, was established.
  • Wada Y; Monzen H; Otsuka M; Inada M; Doi H; Nakamatsu K; Nishimura Y
    Medical Dosimetry In press 2021/10 [Refereed]
  • Takuya Uehara; Hiroshi Doi; Kazuki Ishikawa; Masahiro Inada; Saori Tatsuno; Yutaro Wada; Yasuo Oguma; Hisato Kawakami; Kiyoshi Nakamatsu; Makoto Hosono; Yasumasa Nishimura
    Head & neck 43 (10) 3132 - 3141 2021/07 [Refereed]
     
    BACKGROUND: The present study aimed to evaluate the prognostic factors in human papillomavirus (HPV)-positive and HPV-negative oropharyngeal cancer (OPC) treated with definitive radiotherapy. METHODS: We retrospectively evaluated 101 patients with OPC who underwent definitive radiotherapy between 2008 and 2018. RESULTS: The median follow-up period of the surviving patients was 68 months (range, 8-164 months). The 5-year overall survival rate was 69.8%. Univariate analyses revealed that poor survival was associated with male sex, smoking ≥30 pack-years, Eastern Cooperative Oncology Group performance status ≥1, tumor-node-metastasis (TNM) stage III-IV (8th edition), HPV-negativity, serum lactate dehydrogenase (LDH) ≥202, C-reactive protein/albumin ratio ≥0.15, and lymphocyte-to-monocyte ratio <2.90. In multivariate analyses, poor survival was independently correlated with smoking ≥30 pack-years (p < 0.01) and LDH ≥202 (p = 0.02). CONCLUSIONS: The present study suggested that high LDH levels predicted poor survival after definitive radiotherapy for patients with both HPV-positive and HPV-negative OPC.
  • Masahiro Inada; Yasumasa Nishimura; Kazuki Ishikawa; Takuya Uehara; Yutaro Wada; Yasuo Oguma; Hiroshi Doi; Kiyoshi Nakamatsu
    Esophagus : official journal of the Japan Esophageal Society 18 (3) 638 - 644 2021/07 [Refereed]
     
    BACKGROUND: The role of intensity-modulated radiation therapy in the treatment of cervical esophageal cancer remains unclear. The outcome of concurrent chemoradiotherapy for cervical esophageal squamous cell carcinoma using intensity-modulated radiation therapy was retrospectively evaluated. METHODS: Between 2004 and 2017, 36 patients with cervical esophageal cancer treated with intensity-modulated radiation therapy were included. Among these patients, one had stage II disease, three stage III, 19 stage IVA, and 13 stage IVB. All patients received radiotherapy at a dose of 60 Gy and concurrent platinum-based doublet chemotherapy. RESULTS: The median follow-up period for surviving patients was 36 months. Three-year locoregional control, progression-free survival, and overall survival rates were 54, 40, and 46%, respectively. Disease progression was noted in 20 out of 36 patients (56%). Grade 3 late toxicities were observed in four patients (three esophageal stenoses and one carotid artery stenosis). There were no grade 4-5 toxicities. Univariate analysis identified the duration of radiotherapy as a prognostic factor for overall survival. CONCLUSIONS: Chemoradiotherapy using intensity-modulated radiation therapy for locally advanced cervical esophageal carcinoma achieved satisfactory locoregional control and survival with acceptable toxicities.
  • Yutaro Wada; Hajime Monzen; Mikoto Tamura; Masakazu Otsuka; Masahiro Inada; Kazuki Ishikawa; Hiroshi Doi; Kiyoshi Nakamatsu; Yasumasa Nishimura
    Journal of Medical Physics 46 (1) 7 - 15 2021/01 [Refereed]
     
    PURPOSE: We investigated the performance of the simplified knowledge-based plans (KBPs) in stereotactic body radiotherapy (SBRT) with volumetric-modulated arc therapy (VMAT) for lung cancer. MATERIALS AND METHODS: For 50 cases who underwent SBRT, only three structures were registered into knowledge-based model: total lung, spinal cord, and planning target volume. We performed single auto-optimization on VMAT plans in two steps: 19 cases used for the model training (closed-loop validation) and 16 new cases outside of training set (open-loop validation) for TrueBeam (TB) and Halcyon (Hal) linacs. The dosimetric parameters were compared between clinical plans (CLPs) and KBPs: CLPclosed, KBPclosed-TB and KBPclosed-Hal in closed-loop validation, CLPopen, KBPopen-TB and KBPopen-Hal in open-loop validation. RESULTS: All organs at risk were comparable between CLPs and KBPs except for contralateral lung: V5 of KBPs was approximately 3%-7% higher than that of CLPs. V20 of total lung for KBPs showed comparable to CLPs; CLPclosed vs. KBPclosed-TB and CLPclosed vs. KBPclosed-Hal: 4.36% ± 2.87% vs. 3.54% ± 1.95% and 4.36 ± 2.87% vs. 3.54% ± 1.94% (P = 0.54 and 0.54); CLPopen vs. KBPopen-TB and CLPopen vs. KBPopen-Hal: 4.18% ± 1.57% vs. 3.55% ± 1.27% and 4.18% ± 1.57% vs. 3.67% ± 1.26% (P = 0.19 and 0.27). CI95 of KBPs with both linacs was superior to that of the CLP in closed-loop validation: CLPclosed vs. KBPclosed-TB vs. KBPclosed-Hal: 1.32% ± 0.12% vs. 1.18% ± 0.09% vs. 1.17% ± 0.06% (P < 0.01); and open-loop validation: CLPopen vs. KBPopen-TB vs. KBPopen-Hal: 1.22% ± 0.09% vs. 1.14% ± 0.04% vs. 1.16% ± 0.05% (P ≤ 0.01). CONCLUSIONS: The simplified KBPs with limited number of structures and without planner intervention were clinically acceptable in the dosimetric parameters for lung VMAT-SBRT planning.
  • 画像誘導治療の今後について 頭頸部癌に対する適応放射線治療の必要性
    石川 一樹; 植原 拓也; 稲田 正浩; 土井 啓至; 中松 清志; 西村 恭昌
    日本癌治療学会学術集会抄録集 (一社)日本癌治療学会 58回 SY14 - 1 2020/10
  • 照射後再発に対する治療戦略 再発上咽頭癌に対する治療戦略
    石川 一樹; 稲田 正浩; 植原 拓也; 中松 清志; 西村 恭昌
    頭頸部癌 (一社)日本頭頸部癌学会 46 (2) 112 - 112 1349-5747 2020/07
  • 新TNM分類を検証する 放射線治療に必要なAJCC/UICC TNM分類の知識とその検証
    稲田 正浩; 石川 一樹; 西村 恭昌
    頭頸部癌 (一社)日本頭頸部癌学会 46 (2) 130 - 130 1349-5747 2020/07
  • Eri Inoue; Hiroshi Doi; Hajime Monzen; Mikoto Tamura; Masahiro Inada; Kazuki Ishikawa; Kiyoshi Nakamatsu; Yasumasa Nishimura
    In Vivo Anticancer Research USA Inc. 34 (3) 1095 - 1101 0258-851X 2020/05 [Refereed]
  • Mikoto Tamura; Hajime Monzen; Kenji Matsumoto; Kazuki Kubo; Yoshihiro Ueda; Tatsuya Kamima; Masahiro Inada; Hiroshi Doi; Kiyoshi Nakamatsu; Yasumasa Nishimura
    Journal of Medical Physics Medknow 45 (2) 71 - 77 0971-6203 2020/04 [Refereed]
  • Masahiro Inada; Yasumasa Nishimura; Kazuki Ishikawa; Kiyoshi Nakamatsu; Yutaro Wada; Takuya Uehara; Kohei Fukuda; Shimpei Anami; Hiroshi Doi; Shuichi Kanamori
    Esophagus : official journal of the Japan Esophageal Society 16 (4) 371 - 376 1612-9059 2019/10 [Refereed]
     
    BACKGROUND: We retrospectively compared the 7th and the 8th editions of The American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) TNM classification in the cohort of survival of the patients with esophageal squamous cell carcinoma (ESCC) treated by definitive radiotherapy. METHODS: We included in this study 403 patients with ESCC who underwent radiotherapy or chemoradiotherapy, at a total radiation dose of ≥ 50 Gy with curative intent from 2000 to 2016 at Kindai University Hospital, and who had no distant metastasis (excluding supraclavicular lymph node). The same patient data set was re-staged according to both the 7th and 8th editions of AJCC/UICC TNM classification. RESULTS: For the 7th edition, 5-year overall survival (OS) for stages I, II, III, and IV were 58%, 52%, 22%, and 12%, respectively, which seemed to be separable into two groups (Stages I-II and III-IV). In the 8th edition, corresponding values for stages I, II, III, and IV were 65%, 44%, 34%, and 16%, respectively, which seemed to be separated into three groups (Stage I, II-III, and IV). CONCLUSIONS: The 8th edition of AJCC/UICC TNM classification is a useful predictor of OS among ESCC patients who were treated with definitive radiotherapy.
  • Shimpei Anami; Hiroshi Doi; Kiyoshi Nakamatsu; Takuya Uehara; Yutaro Wada; Kohei Fukuda; Masahiro Inada; Kazuki Ishikawa; Shuichi Kanamori; Yasumasa Nishimura
    Journal of radiation research 60 (2) 257 - 263 0449-3060 2019/03 [Refereed]
     
    This study aimed to identify factors that predict prognosis after radiotherapy for brain metastases (BMs) from small-cell lung cancer (SCLC). This study retrospectively evaluated 48 consecutive patients who underwent whole-brain radiotherapy (WBRT) for BMs from SCLC between February 2008 and December 2017. WBRT was delivered at a median dose of 30 Gy (range: 30-40 Gy) in 10 fractions (range: 10-16 fractions). Clinical factors were tested for associations with overall survival after WBRT. The median survival and 1-year overall survival rate after WBRT treatment were 232 days and 34.4%, respectively. Univariate analyses revealed that longer survival was associated with Eastern Cooperative Oncology Group performance status of 0-1, asymptomatic BMs, lactate dehydrogenase (LDH) in the normal range, Radiation Therapy Oncology Group-recursive partitioning analysis class 2, and a graded prognostic assessment score of ≥1.5 (P < 0.01, P < 0.01, P < 0.01, P < 0.01 and P < 0.05, respectively). In the multivariate analyses, longer survival was independently associated with asymptomatic BMs [hazard ratio for death (HR), 0.32; 95% confidence interval (CI), 0.12-0.79; P < 0.05] and LDH in the normal range (HR, 0.42; 95% CI, 0.21-0.83; P < 0.05). The presence of symptoms due to BMs and LDH values independently predicted prognosis after WBRT for BMs from SCLC. Elevated LDH may provide valuable information for identifying patients with BMs who could have poor survival outcomes.
  • Doi, Hiroshi; Nakamatsu, Kiyoshi; Anami, Shimpei; Fukuda, Kohei; Inada, Masahiro; Tatebe, Hitoshi; Ishikawa, Kazuki; Kanamori, Shuichi; Monzen, Hajime; Nishimura, Yasumasa
    IN VIVO INT INST ANTICANCER RESEARCH 33 (1) 195 - 201 0258-851X 2019/01 [Refereed]
     
    Aim: This study aimed to identify prognostic factors for response to whole-brain radiotherapy (WBRT) in patients with brain metastases (BMs) from non-small cell lung cancer (NSCLC). Patients and Methods: This study retrospectively evaluated 100 patients who underwent WBRT for BMs from NSCLC between December 2012 and October 2017. Clinical factors were tested for associations with overall survival after WBRT. Results: The median follow-up time was 134 days (range=14-1,395 days), the median survival time was 143 days, and the 1-year survival rate was 30.4%. Univariate and multivariate analyses revealed that better survival was independently associated with expression of programmed death-ligand 1 (PD-L1), no previous treatment for BMs, no extracranial disease, and a neutrophil-to-lymphocyte ratio (NLR) of <5.0. Conclusion: A low NLR and positive PD-L1 expression independently predict better prognosis in patients with BMs from NSCLC after WBRT. These findings suggest that the potential immune response may influence survival among patients with BMs.
  • Otsuka M; Monzen H; Matsumoto K; Tamura M; Inada M; Kadoya N; Nishimura Y
    PloS one 14 (11) e0225965  2019 [Refereed]
  • Izumi Tachibana; Yasumasa Nishimura; Masahiro Inada; Kohei Fukuda; Kazuki Ishikawa; Tatsuyuki Nishikawa; Masaki Yokokawa; Kiyoshi Nakamatsu; Shuichi Kanamori; Jin-Ichi Hida
    International journal of clinical oncology 23 (6) 1121 - 1126 1341-9625 2018/12 [Refereed]
     
    BACKGROUND: Chemoradiotherapy (CRT) is a standard treatment for anal canal cancer although many patients with anal canal cancer undergo surgery in Japan. The efficacy of CRT for anal canal cancer was evaluated retrospectively. METHODS: Medical charts of 13 patients with anal canal cancer treated by definitive CRT from October 2004 to May 2016 were reviewed. Twelve patients had squamous cell carcinoma and one had adeno-squamous carcinoma. PET/CT simulation was performed in nine patients. The median total dose was 59.4 Gy (range 57.6-63.4 Gy) with fractions of 1.8-2.0 Gy. Ten patients received chemotherapy with mitomycin C (10 mg/m2) and fluorouracil (5-FU) (800 mg/m2 over 4 days) in weeks 1 and 5, while two patients were treated with cisplatin (40 mg) and 5-FU (750 mg over 5 days) in weeks 1 and 5. One elderly patient received radiotherapy (RT) alone. RESULTS: All 13 patients were alive after a median follow-up period of 102 months (range 16-121 months). Local failure only occurred in the patient with adeno-squamous cell carcinoma, while there was no loco-regional recurrence or distant metastasis in the other 12 patients. The 5-year loco-regional control rate (LRC) and 5-year overall survival rate (OS) were 92% and 100%, respectively. Acute toxicities of ≥ grade 3 were observed in six patients (46%), mainly being dermatitis around the anal verge, and late toxicity of ≥ grade 3 occurred in one patient. CONCLUSION: CRT for squamous cell carcinoma of the anal canal achieved good LRC and OS with acceptable toxicities.
  • Mikoto Tamura; Hajime Monzen; Kenji Matsumoto; Kazuki Kubo; Masakazu Otsuka; Masahiro Inada; Hiroshi Doi; Kazuki Ishikawa; Kiyoshi Nakamatsu; Iori Sumida; Hirokazu Mizuno; Do-Kun Yoon; Yasumasa Nishimura
    Radiation oncology (London, England) 13 (1) 163 - 163 2018/08 [Refereed]
     
    BACKGROUND: This study clarified the mechanical performance of volumetric modulated arc therapy (VMAT) plans for prostate cancer generated with a commercial knowledge-based treatment planning (KBP) and whether KBP system could be applied clinically without any major problems with mechanical performance. METHODS: Thirty consecutive prostate cancer patients who underwent VMAT using extant clinical plans were evaluated. The mechanical performance and dosimetric accuracy of the single optimized KBPs, which were trained with other 51 clinical plans, were compared with the clinical plans. The mechanical performance metrics were mean field area (MFA), mean asymmetry distance (MAD), cross-axis score (CAS), closed leaf score (CLS), small aperture score (SAS), leaf travel (LT), modulation complexity score (MCSv), and monitor unit (MU). The γ passing rates were evaluated with ArcCheck and EBT3 film. RESULTS: The mean mechanical performance metrics (clinical plan vs. KBP) were as follows: 18.28 cm2 vs. 17.25 cm2 (MFA), 21.08 mm vs. 20.47 mm (MAD), 0.54 vs. 0.55 (CAS), 0.040 vs. 0.051 (CLS), 0.20 vs. 0.23 (SAS5mm), 458.5 mm vs. 418.8 mm (LT), 0.27 vs. 0.27 (MCSv), and 618.2 vs. 622.1 (MU), respectively. Significant differences were observed for CLS and LT. The average γ passing rates (clinical plan vs. KBP) were as follows: 99.0% vs. 99.1% (3%/3 mm) and 92.4% vs. 92.5% (2%/2 mm) with ArcCHeck, and 99.5% vs. 99.4% (3%/3 mm) and 95.2% vs. 95.4% (2%/2 mm) with EBT3 film, respectively. CONCLUSIONS: The KBP used lower multileaf collimator (MLC) travel and more closed or small MLC apertures than the clinical plan. The KBP system of VMAT for the prostate cancer was acceptable for clinical use without any major problems.
  • Masahiro Inada; Hajime Monzen; Kenji Matsumoto; Mikoto Tamura; Takafumi Minami; Kiyoshi Nakamatsu; Yasumasa Nishimura
    Journal of radiation research 59 (3) 333 - 337 0449-3060 2018/05 [Refereed]
     
    Tungsten functional paper (TFP) is a paper-based radiation-shielding material, which is lead-free and easy to cut. We developed a radiation protection undergarment using TFP for prostate cancer patients treated with permanent 125I seed implantation (PSI). The aim of this study was to evaluate the shielding ability of the undergarment with respect to household contacts and members of the public. Between October 2016 and April 2017, a total of 10 prostate cancer patients treated with PSI were enrolled in this prospective study. The external radiation exposure from each patient 1 day after PSI was measured with and without the undergarment. Measurements were performed using a survey meter at 100 cm from the surface of the patient's body. The exposure rates were measured from five directions: anterior, anteriorly oblique, lateral, posteriorly oblique, and posterior. The measured radiation exposure rates without the undergarment, expressed as mean ± standard deviation, from the anterior, anteriorly oblique, lateral, posteriorly oblique, and posterior directions were 1.28 ± 0.43 μSv/h, 0.70 ± 0.34 μSv/h, 0.21 ± 0.062 μSv/h, 0.65 ± 0.33 μSv/h and 1.24 ± 0.41 μSv/h, respectively. The undergarment was found to have (mean ± standard deviation) shielding abilities of 88.7 ± 5.8%, 44.0 ± 42.1%, 50.6 ± 15.9%, 72.9 ± 27.0% and 90.4 ± 10.7% from the anterior, anteriorly oblique, lateral, posteriorly oblique, and posterior directions, respectively. In conclusion, this shielding undergarment is a useful device that has the potential to reduce radiation exposure for the general public and the patient's family.
  • Izumi Tachibana; Yasumasa Nishimura; Kohei Hanaoka; Masahiro Inada; Kohei Fukuda; Hitoshi Tatebe; Kazuki Ishikawa; Kiyoshi Nakamatsu; Shuichi Kanamori; Makoto Hosono
    Anticancer research 38 (3) 1775 - 1781 0250-7005 2018/03 [Refereed]
     
    BACKGROUND/AIM: 18F-misonidazole positron emission tomography (FMISO PET)/computed tomography (CT) obtained before and during radiotherapy (RT) was analyzed as to whether it could predict clinical outcome. PATIENTS AND METHODS: Twenty-two patients were included. FMISO PET/ CT was performed twice before RT and at a dose of approximately 20 Gy/10 fractions. FMISO maximum standardized uptake values (SUVmax), the tumor-to-muscle ratios (T/M), and hypoxic volume (HV) in gross target volumes were measured. RESULTS: Of the 22 tumors, 18 had hypoxic areas (SUVmax ≥1.60) before RT. SUVmax, T/M, and HV on the first PET/CT were significantly correlated with initial tumor response, although the values during RT were not related to the response. The overall survival and loco-regional control rates of patients below cut-off values were significantly better than those above the cut-off values. CONCLUSION: Tumor hypoxia detected by FMISO PET/CT before RT may predict clinical outcome.
  • Masakazu Otsuka; Hajime Monzen; Kenji Matsumoto; Mikoto Tamura; Masahiro Inada; Noriyuki Kadoya; Yasumasa Nishimura
    PloS one 13 (10) e0204721  2018 [Refereed]
     
    BACKGROUND: Four-dimensional computed tomography (4D-CT) ventilation is an emerging imaging modality. Functional avoidance of regions according to 4D-CT ventilation may reduce lung toxicity after radiation therapy. This study evaluated associations between 4D-CT ventilation-based dosimetric parameters and clinical outcomes. METHODS: Pre-treatment 4D-CT data were used to retrospectively construct ventilation images for 40 thoracic cancer patients retrospectively. Fifteen patients were treated with conventional radiation therapy, 6 patients with hyperfractionated radiation therapy and 19 patients with stereotactic body radiation therapy (SBRT). Ventilation images were calculated from 4D-CT data using a deformable image registration and Jacobian-based algorithm. Each ventilation map was normalized by converting it to percentile images. Ventilation-based dosimetric parameters (Mean Dose, V5 [percent lung volume receiving ≥5 Gy], and V20 [percent lung volume receiving ≥20 Gy]) were calculated for highly and poorly ventilated regions. To test whether the ventilation-based dosimetric parameters could be used predict radiation pneumonitis of ≥Grade 2, the area under the curve (AUC) was determined from the receiver operating characteristic analysis. RESULTS: For Mean Dose, poorly ventilated lung regions in the 0-30% range showed the highest AUC value (0.809; 95% confidence interval [CI], 0.663-0.955). For V20, poorly ventilated lung regions in the 0-20% range had the highest AUC value (0.774; 95% [CI], 0.598-0.915), and for V5, poorly ventilated lung regions in the 0-30% range had the highest AUC value (0.843; 95% [CI], 0.732-0.954). The highest AUC values for Mean Dose, V20, and V5 were obtained in poorly ventilated regions. There were significant differences in all dosimetric parameters between radiation pneumonitis of Grade 1 and Grade ≥2. CONCLUSIONS: Poorly ventilated lung regions identified on 4D-CT had higher AUC values than highly ventilated regions, suggesting that functional planning based on poorly ventilated regions may reduce the risk of lung toxicity in radiation therapy.
  • Masahiro Inada; Masaki Yokokawa; Takafumi Minami; Kiyoshi Nakamatsu; Yasumasa Nishimura
    Journal of contemporary brachytherapy TERMEDIA PUBLISHING HOUSE LTD 9 (5) 410 - 417 1689-832X 2017/10 [Refereed]
     
    Purpose: The aim of this study was to compare the implant quality between intraoperatively built custom-linked seeds (IBCL) and loose seeds (LS) retrospectively. Material and methods: This study included 74 prostate cancer patients who were treated with permanent prostate brachytherapy (PPB) using IBCL (n = 37) or LS (n = 37) between July 2014 and June 2016. Dose-volume histogram (DVH) parameters, seed migration, and operation time were compared between the IBCL and LS groups. In addition to the standard target volume of the whole prostate gland, DVH parameters for prostate plus a 3 mm margin (CTV) were evaluated. Results: In intraoperative planning, prostate V150 was lower (54.8% vs. 59.6%, p = 0.027), and CTV V100 (88.1% vs. 85.6%, p = 0.019) and D90 (98.5% vs. 92.6%, p = 0.0033) were higher in the IBCL group compared with in the LS group. In post-implant dosimetry, prostate V100 (96.9% vs. 95.2%, p = 0.020), CTV V100 (85.6% vs. 81.7%, p = 0.046), and CTV D90 (94.2% vs. 86.5%, p < 0.001) were higher, and prostate V150 (57.1% vs. 64.5%, p = 0.0051) and CTV V150 (31.5% vs. 35.7%, p = 0.046) were lower in the IBCL group compared with in the LS group. Regarding DVH changes between intraoperative planning and post-implant dosimetry, the decrease in prostate D90 was significantly lower in the IBCL group than in the LS group (-1.16% vs. -4.17%, p < 0.001). For the IBCL group, the operation time was slightly but significantly longer than that for the LS group (50.5 minutes vs. 43.7 minutes, p = 0.011). However, the seed migration rate was significantly lower in the IBCL group than in the LS group (5% vs. 41%, p < 0.001). Conclusions: Intraoperatively built custom-linked is more advantageous than LS in terms of dosimetric parameters and migration.
  • 稲田 正浩; 西村 恭昌; 石川 一樹; 花岡 宏平; 坂口 健太; 細野 眞
    臨床放射線 金原出版 61 (5) 657 - 666 0009-9252 2016/05 [Invited]

Conference Activities & Talks

  • 頭頸部強度変調放射線治療における 計算アルゴリズムがアウトカムに与える影響  [Not invited]
    稲田正浩; 植原拓也; 立野沙織; 松浦知弘; 石田奈緒子; 李在俊; 土井啓至; 中松清志; 細野眞; 松尾幸憲; 西村恭昌
    日本放射線腫瘍学会第36回学術大会  2023/12
  • 遠隔転移を伴う食道癌に対する高線量緩和的化学放射線療法の意義  [Not invited]
    稲田正浩
    第77回日本食道学会学術集会  2023/06
  • 近畿大学病院における頭頸部IMRTのノウハウ  [Invited]
    稲田正浩
    第36回高精度放射線学術大会  2023/03
  • 肺癌定位放射線治療における低酸素トレーサーを用いた低酸素領域と再酸素化現象の画像化の前向き臨床試験  [Not invited]
    稲田正浩
    第36回高精度放射線学術大会  2023/03
  • F-MISO PETを用いた肺癌体幹部定位放射線治療における再酸素化現象の画像化  [Not invited]
    稲田正浩
    日本放射線腫瘍学会 第35回学術大会  2022/11
  • The Organs-at-Risk Dose Constraints in Head and Neck Intensity Modulated Radiation Therapy Using Data from a Multi-Institutional Clinical Trial (JCOG1015A1)  [Not invited]
    M. Inada; Y. Nishimura; S. Ishikura; K. Ishikawa; N. Murakami; T. Kodaira; Y. Ito; K. Tsuchiya; Y. Murakami; J.I. Saitoh; T. Akimoto; K. Nakata; M. Yoshimura; T. Teshima; T. Toshiyasu; Y. Ota; T. Minemura; H. Shimizu; M. Hiraoka
    American Society for Radiation Oncology, Annual meeting 2022  2022/10
  • 肝機能障害を有する食道癌患者に対する放射線治療の検討  [Not invited]
    稲田正浩
    第76回 日本食道学会学術集会  2022/09
  • FDG-PET/CTによる放射線治療計画と治療後の経過観察  [Invited]
    稲田正浩
    PETサマーセミナー2022 in甲府  2022/07
  • 当院における上顎洞癌に対する超選択的動注化学療法併用放射線療法の遡及的検討  [Not invited]
    稲田正浩; 石川一樹; 植原拓也; 西村恭昌
    第46回日本頭頸部癌学会  2022/06
  • 頭頸部強度変調放射線治療における臓器特異的耐 容線量の解明（JCOG1015A1）  [Not invited]
    稲田 正浩; 西村 恭昌; 石川 一樹; 村上 直也; 石倉 聡; 古平 毅; 伊藤 芳紀; 土屋 和彦; 村上 祐司; 齋藤 淳一; 秋元 哲夫; 峯村 俊
    日本放射線腫瘍学会 第34回学術大会  2021/11
  • 当院における喉頭癌に対する加速過分割照射の成績  [Not invited]
    稲田正浩; 西村恭昌; 石川一樹; 植原拓也; 和田祐太郎; 大熊康央; 土井啓至; 中松清志; 細野眞
    日本放射線腫瘍学会第33回学術大会  2020/10
  • 放射線治療に必要なAJCC/UICC TNM分類の知識とその検証  [Invited]
    稲田正浩
    第44回日本頭頸部癌学会  2020/07
  • 上咽頭癌化学放射線療法における予後予測マーカーとしてのLactate dehydrogenaseの有効性の検討  [Not invited]
    INADA MASAHIRO
    The 32th annual meeting of the Japanese Society of Radiation Oncology  2019/10
  • 当院における低リスク前立腺癌に対する密封小線源永久挿入単独療法  [Not invited]
    稲田正浩; 中松清志; 植原拓也; 和田祐太郎; 福田浩平; 阿南慎平; 石川一樹; 土井啓至; 金森修一; 西村恭昌
    日本放射線腫瘍学会 小線源治療部会第21回学術大会  2019/05
  • 食道扁平上皮癌に対する放射線治療の成績：UICC TNM分類第7版と第8版の比較  [Not invited]
    稲田正浩; 石川一樹; 植原拓也; 和田祐太郎; 福田浩平; 阿南慎平; 土井啓至; 中松清志; 金森修一; 西村恭昌
    日本放射線腫瘍学会第31回学術大会  2018/10
  • StageⅠ-Ⅱ食道扁平上皮癌に対する放射線 治療成績：UICC TNM分類第7版と第8版の比較  [Not invited]
    稲田正浩; 石川一樹; 中松清志; 西村恭昌
    日本食道学会第72回学術大会  2018/06
  • 当院における高リスク前立腺癌に対する外照射併用密封小線源永久挿入療法の5年成績  [Not invited]
    稲田正浩; 中松清志; 植原拓也; 和田祐太郎; 阿南慎平; 福田浩平; 石川一樹; 土井啓至; 金森修一; 西村恭昌
    日本放射線腫瘍学会 小線源治療部会第20回学術大会  2018/06
  • 中リスク前立腺癌に対する密封小線源永久挿入療法の5年成績  [Not invited]
    稲田正浩; 中松清志; 福田浩平; 建部仁志; 石川一樹; 金森修一; 西村恭昌
    日本放射線腫瘍学会第30回学術大会  2017/11
  • 前立腺シード療法における 連結型シードと分離型シードのDosimetry比較  [Not invited]
    稲田正浩; 中松清志; 福田浩平; 建部仁志; 石川一樹; 金森修一; 西村恭昌
    日本医学放射線学会第317回関西地方会  2017/11
  • Dosimetry comparison between intraoperatively built custom linked seeds and loose seeds in permanent prostate brachytherapy: Do intraoperative built custom linked seeds improve dosimetry of prostate margin?  [Not invited]
    INADAMASAHIRO
    American Society for Radiation Oncology 2017 Annual Meeting  2017/09
  • 食道癌根治術後肺oligometastasisに対し定位放射線療法を施行した3例の検討  [Not invited]
    稲田正浩; 石川一樹; 中松清志; 西村恭昌
    第71回日本食道学会学術集会  2017/06
  • 前立腺癌ヨウ素125線源挿入患者に向けたタングステン機能紙を用いた新放射線防護着の開発  [Not invited]
    INADA MASAHIRO
    日本放射線腫瘍学会 第19回小線源部会学術大会  2017/05
  • Brachy MonotherapyにおけるOncoseedとQuickLinkの DVH比較  [Not invited]
    稲田正浩; 横川正樹; 南高文; 中松清志; 西村恭昌
    第13回前立腺癌密封小線源永久挿入治療研究会  2017/01
  • 前立腺癌密封小線源永久挿入療法における連結型シード線源使用の初期経験  [Not invited]
    稲田正浩; 横川正樹; 中松清志; 福田浩平; 建部仁志; 石川一樹; 金森修一; 西村恭昌
    第29回日本放射線腫瘍学学術集会  2016/11
  • 局所進行直腸癌に対する術前化学放射線療法8例の検討  [Not invited]
    稲田正浩; 福田浩平; 建部仁志; 西川龍之; 石川一樹; 中松清志; 金森修一; 西村恭昌
    第314回日本医学放射線学会関西地方会  2016/11
  • 局所進行直腸癌に対する術前化学放射線療法の初期経験  [Not invited]
    稲田正浩; 川村純一郎; 福田浩平; 建部仁志; 石川一樹; 中松清志; 金森修一; 吉岡康多; 大東弘治; 上田和毅; 肥田仁一; 奥野清隆; 西村恭昌
    第16回近畿放射線医学フォーラム  2016/10
  • Change of myocardial FDG uptake pattern after radiotherapy for esophageal cancer  [Not invited]
    MASAHIRO INADA
    The58th American Society of Radiation Oncology Annual Meeting  2016/09
  • Treatment outcome of radiotherapy for Stage ⅠA esophageal cancer  [Not invited]
    INADA MASAHIRO; ISHIKAWA KAZUKI; NAKAMATSU KIYOSHI; NISHIMURA YASUMASA
    The 70th Annual Meeting of the Japan Esophageal Society  2016/07
  • 放射線治療と核医学とのコラボレーション 放射線による心毒性と心筋シンチ  [Invited]
    INADAMASAHIRO
    im022012  2015/11
  • Radiotherapy for recurrent pleuropulmonary blastoma after chemotherapy and surgery.  [Not invited]
    INADA MASAHIRO; KANAMORI SHUICH; FUKUDA KOHEI; TATEBE HITOSHI; ISHIKAWA KAZUKI; TACHIBANA IZUMI; YOKOKAWA MASAKI; NAKAMATSU KIYOSHI; NISHIMURA YASUMASA
    The 28th Annual Meeting of the Japanese Society for Radiation Oncology  2015/11
  • 胸部食道癌放射線治療後の心筋FDG-PET/CT所見の検討  [Not invited]
    INADAMASAHIRO
    The 69th annual meeting of THE JAPAN ESOPHAGEAL SOCIETY  2015/07
  • Myocardial changes on FDG-PET/CT after radiation therapy for esophageal cancer  [Not invited]
    INADAMASAHIRO
    The 15th International Congress of Radiation Research  2015/05
  • Myocardial changes on FDG-PET/CT after radiation therapy for esophageal cancer  [Not invited]
    INADAMASAHIRO
    The 74th Annual Meeting of the Japan Radiological Society  2015/04
  • Myocardial changes on FDG-PET/CT after radiation therapy for esophageal cancer  [Not invited]
    INADAMASAHIRO
    第14回近畿放射線医学フォーラム  2014/10

MISC

Awards & Honors

  • 2021/12 近畿大学医学部 Award of Medical Society of Kindai University
     Outcome of chemoradiotherapy using intensity-modulated radiation therapy for cervical esophageal cancer: a single institute experience. Esophagus. 2021 Jul;18(3):638-644. 
    受賞者: Masahiro Inada

Research Grants & Projects

  • 日本学術振興会：科学研究費助成事業
    Date (from‐to) : 2020/04 -2023/03 
    Author : 西村 恭昌; 稲田 正浩; 石川 一樹
     
    本研究は、日本臨床腫瘍研究グループ（JCOG）で行った「上咽頭癌に対する強度変調放射線治療（IMRT）の多施設共同第II相試験（JCOG1015）」の線量体積ヒストグラム（DVH）と患者データを用いて、晩期有害事象と正常臓器の線量効果関係を明らかにする研究である。本研究は2020年8月にJCOGプロトコール審査委員会で承認され、さらに2020年に9月に近畿大学医学部で、2021年2月に国立研究開発法人国立がん研究センターの倫理委員会で承認された。 2021年度には、これらのデータを基に、内耳Dmean（平均線量)、甲状腺Dmean、水晶体Dmean、眼球Dmax（最大線量）、視神経Dmax、耳下腺Dmedian（中央線量）, 耳下腺Dmean、中下咽頭収縮筋Dmean、喉頭Dmean、頸髄Dmax, 頸髄D1cc（1cc線量）、脳Dmax, 脳D1cc、脳幹Dmax, 脳幹D1ccなどのDVH因子と臓器特異的晩期有害事象との線量効果関係を検討した。その結果、脊髄炎G1以上と脳幹D1cc≧55.8Gy、中枢神経壊死G1以上と脳D1cc≧72.1Gy、聴覚障害G2以上と内耳Dmean≧44Gy、および中耳炎G2以上と内耳Dmean≧51.5Gyとの間に有意な線量依存関係が確認された。また、嚥下障害G2以上と中下咽頭収縮筋Dmean ≧41.2Gy、および甲状腺機能低下G1以上と甲状腺Dmean ≧45.6Gyとの間に線量依存傾向がみられた。JCOG1015では聴覚障害・中耳炎、脊髄炎の頻度が比較的高く、内耳および脳幹線量との相関が見られたため、内耳、脳幹線量のさらなる低減が望ましいと考えられた。以上の結果は、2021年11月にオンライン開催された第34回日本放射線腫瘍学会で発表した。その後、英文原著論文として執筆中である。
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2016/04 -2020/03 
    Author : NISHIMURA Yasumasa
     
    To evaluate the necessity of adaptive radiation therapy (ART) for head and neck cancer, a prospective clinical trial was conducted using in-room cone-beam CT. Parotid glands and planning target volume (PTV) decreased in volume significantly during a 5-week period. However, no decrease of PTV dose was noted. Maximum doses of the spinal cord and brain stem increased significantly in more than 10% of the patients 2 weeks after treatment. Re-planning might be necessary for these patients. Knowledge-based planning (KBP) approach can improve speed and efficiency of treatment planning process. KBP plans and clinical manual plans were compared for prostate cancer and head and neck cancer. In both studies, KBP plans were comparable or superior to clinical manual plans. KBP approach was acceptable for clinical use.

Other link

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.